908 Devices (NASDAQ:MASS) Given Sell (E+) Rating at Weiss Ratings

908 Devices (NASDAQ:MASS)‘s stock had its “sell (e+)” rating reiterated by equities researchers at Weiss Ratings in a research report issued to clients and investors on Saturday,Weiss Ratings reports.

Separately, Stephens restated an “overweight” rating and issued a $6.00 target price on shares of 908 Devices in a research report on Wednesday, January 15th. Two investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, 908 Devices has an average rating of “Moderate Buy” and a consensus price target of $5.33.

908 Devices Stock Up 8.9 %

NASDAQ:MASS opened at $4.53 on Friday. 908 Devices has a 52 week low of $1.81 and a 52 week high of $7.56. The company has a market capitalization of $160.04 million, a P/E ratio of -2.56 and a beta of 0.99. The stock’s fifty day moving average is $2.91 and its two-hundred day moving average is $2.92.

Institutional Investors Weigh In On 908 Devices

Several institutional investors and hedge funds have recently modified their holdings of MASS. Two Sigma Advisers LP purchased a new stake in shares of 908 Devices in the 4th quarter valued at $30,000. Prudential Financial Inc. purchased a new stake in shares of 908 Devices in the 4th quarter valued at $34,000. Occudo Quantitative Strategies LP purchased a new stake in shares of 908 Devices in the 4th quarter valued at $36,000. Two Sigma Investments LP purchased a new stake in shares of 908 Devices in the 4th quarter valued at $42,000. Finally, B. Riley Wealth Advisors Inc. purchased a new stake in shares of 908 Devices in the 3rd quarter valued at $45,000. Hedge funds and other institutional investors own 88.06% of the company’s stock.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.